Alvin J. Glasky, PhD. to Present Findings on Alzheimer's Therapy; Breakthrough Technology Generates New Nerve Cells and Restores Memory Impairments.IRVINE, Calif.--(BW HealthWire)--Oct. 17, 1997--Alvin J. Glasky, Ph.D., president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of NeoTherapeutics, Inc., will present research findings on AIT-082, a potential new therapy for the treatment of memory impairments associated with Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. , stroke and spinal cord injuries, at the Society for Neuroscience For other uses, see SFN (disambiguation). The Society for Neuroscience (SfN) is a professional society for basic scientists and physicians around the world whose research is focused on the study of the brain and nervous system. annual meeting in New Orleans, La. AIT-082, is the first drug in human clinical trials which was specifically designed to be orally active and promote nerve regeneration nerve regeneration Physiology The regrowth and reconnection of viable and functional neural connections damaged by transection or other trauma . It has recently completed two Phase I clinical trials. The primary presentation will discuss the ability of AIT-082 to restore memory impairments. Dr. Glasky will make two poster presentations regarding AIT-082: Tuesday, October 28 from 8:00 a.m. - 12:00 p.m. and Wednesday, October 29 from 8:00 a.m. - 12:00 p.m. Both will take place in the Ernest N. Morial Convention Center The Ernest N. Morial Convention Center is a collection of buildings in New Orleans, Louisiana. The lower end of building one is located 500 m (1640 feet) upriver from Canal Street on the banks of the Mississippi River. Named after former mayor of New Orleans Ernest N. , 900 Convention Center Blvd. Glasky will also be available for one-on-one interviews during the conference. Pre-clinical studies have demonstrated that AIT-082 enhances cognitive function cognitive function Neurology Any mental process that involves symbolic operations–eg, perception, memory, creation of imagery, and thinking; CFs encompasses awareness and capacity for judgment and memory in animals with neurological deficits. It is a novel small molecule that is designed to cross the blood-brain barrier blood-brain barrier n. Abbr. BBB A physiological mechanism that alters the permeability of brain capillaries so that some substances, such as certain drugs, are prevented from entering brain tissue, while other substances are allowed to and enhance nerve cell function by increasing levels of neurotrophic factors. Laboratory studies have shown that AIT-082 has unique properties in that it is able to stimulate the production of neurotrophins, natural proteins that promote the growth and regeneration of nerve cells. "We believe that our drug is working by generating new nerves. In other words Adv. 1. in other words - otherwise stated; "in other words, we are broke" put differently , no matter how Alzheimer's disease occurs or how nerve cells are killed, we are hopeful that our drug will cause new cells to be regenerated," stated Glasky. "Our drug turns on the genes inside the brain to produce natural substances that control nerve multiplication and growth. Our research has shown that AIT-082 can augment and mimic neurotrophic activity," he added. Currently available treatments for Alzheimer's and Parkinson's diseases, neurological trauma, stroke and infections associated with AIDS do not address the underlying problem of neuronal degeneration and therefore, are of limited benefit. Accordingly, a treatment to slow or reverse the actual process of neuronal degeneration remains of vital clinical importance. NeoTherapeutics is engaged in the discovery and development of new drugs that act on the central nervous system to treat neurodegenerative diseases and conditions associated with Alzheimer's disease, impairment associated with the dementia of aging, stroke, spinal cord injuries and the neurological aspects of AIDS. CONTACT: NeoTherapeutics Scott Marx, 415/764-1348 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion